Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Ongoing Clinical Trials for Polycystic Ovarian Syndrome (PCOS) Afflicted Infertility in Women: A Narrative Review

Author(s): Ratnakar Shukla*, Muskan Chadha, Anisha Adya, Aastha Yadav, Nidhi Singh, Ranjeet Singh Chauhan, Afza Ahmad and Rohit Kumar Tiwari*

Volume 20, Issue 2, 2025

Published on: 17 October, 2024

Page: [113 - 123] Pages: 11

DOI: 10.2174/0115748871325070241008101355

Price: $65

TIMBC 2026
Abstract

Polycystic Ovary Syndrome (PCOS) is a highly prevalent endocrine disorder that affects women of reproductive age. PCOS is further correlated with infertility, menstrual dysfunction, and hyperandrogenism. Despite the advanced understanding of reproductive biology, the exact causes of PCOS remain ambiguous. Nevertheless, several factors are believed to contribute to the development of PCOS, including insulin resistance, hyperinsulinemia, obesity, and genetic predispositions. The diagnosis of PCOS is complicated by its phenotypic heterogeneity, which manifests differently in different individuals. Presently, the therapeutic management of PCOS-afflicted infertility depends upon proper pharmaceutical-based therapies aimed at treating underlying symptoms, such as the use of clomiphene citrate, metformin, ovulation-inducing agents, anti-androgens, exogenous gonadotropin administration, laparoscopic ovarian drilling, and in vitro fertilization. The present review focuses on narrating present therapeutic interventions along with lifestyle modifications in PCOS. Furthermore, it focuses on the ongoing clinical trials of various chemotherapeutics to counter PCOS-induced infertility among women.

Keywords: PCOS, infertility, endocrine disorder, therapeutics, insulin resistance, metformin.

Next »
Graphical Abstract

[1]
Pundir CS, Deswal R, Narwal V, Dang A. The prevalence of polycystic ovary syndrome: A brief systematic review. J Hum Reprod Sci 2020; 13(4): 261-71.
[http://dx.doi.org/10.4103/jhrs.JHRS_95_18] [PMID: 33627974]
[2]
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29(2): 181-91.
[http://dx.doi.org/10.1016/S0002-9378(15)30642-6]
[3]
Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod 2021; 36(4): 1108-19.
[http://dx.doi.org/10.1093/humrep/deaa371] [PMID: 33501984]
[4]
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome†. Hum Reprod 2018; 33(9): 1602-18.
[http://dx.doi.org/10.1093/humrep/dey256] [PMID: 30052961]
[5]
Alchami A, O’Donovan O, Davies M. PCOS: diagnosis and management of related infertility. Obstetrics, Gynaecol Reprod Med 2015; 25(10): 279-82.
[http://dx.doi.org/10.1016/j.ogrm.2015.07.005]
[6]
Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: Do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012; 24(1): 6-22.
[http://dx.doi.org/10.1016/j.rbmo.2011.09.017] [PMID: 22133908]
[7]
Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: Overview and approaches for treatment. Diabetes Spectr 2015; 28(2): 116-20.
[http://dx.doi.org/10.2337/diaspect.28.2.116] [PMID: 25987810]
[8]
Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): An update. Arch Gynecol Obstet 2021; 303(3): 631-43.
[http://dx.doi.org/10.1007/s00404-020-05951-2] [PMID: 33439300]
[9]
Definitions of infertility and recurrent pregnancy loss: A committee opinion. Fertil Steril 2013; 99(1): 63.
[http://dx.doi.org/10.1016/j.fertnstert.2012.09.023] [PMID: 23095139]
[10]
Eshire TT. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89(3): 505-22.
[http://dx.doi.org/10.1016/j.fertnstert.2007.09.041] [PMID: 18243179]
[11]
Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet 2022; 39(11): 2439-73.
[http://dx.doi.org/10.1007/s10815-022-02625-7] [PMID: 36190593]
[12]
Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75(1): 53-8.
[http://dx.doi.org/10.1016/S0015-0282(00)01662-9] [PMID: 11163816]
[13]
Legro RS, Driscoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998; 95(25): 14956-60.
[http://dx.doi.org/10.1073/pnas.95.25.14956] [PMID: 9843997]
[14]
Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. Eur J Obstet Gynecol Reprod Biol X 2019; 3: 100060.
[http://dx.doi.org/10.1016/j.eurox.2019.100060] [PMID: 31403134]
[15]
Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14(5): 270-84.
[http://dx.doi.org/10.1038/nrendo.2018.24] [PMID: 29569621]
[16]
Harada M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reprod Med Biol 2022; 21(1): e12487.
[http://dx.doi.org/10.1002/rmb2.12487] [PMID: 36310656]
[17]
Diamanti-Kandarakis E. Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008; 10: e3.
[http://dx.doi.org/10.1017/S1462399408000598] [PMID: 18230193]
[18]
Soni T, Prabhakar PK. Pathophysiology of polycystic ovarian syndrome. Polycystic Ovary Syndrome-Functional Investigation and Clinical Application. IntechOpen 2022.
[19]
Kanbour SA, Dobs AS. Hyperandrogenism in women with polycystic ovarian syndrome: Pathophysiology and controversies. Androgens. Androgens: Clinical Research and Therapeutics 2022; 3(1): 22-30.
[http://dx.doi.org/10.1089/andro.2021.0020]
[20]
Strange RC, König CS, Puttanna A, et al. Klinefelters syndrome: Change in T -scores with testosterone, bisphosphonate, and vitamin D treatment over 6 years. Androgens: Clinical Research and Therapeutics 2021; 2(1): 111-20.
[http://dx.doi.org/10.1089/andro.2021.0002]
[21]
Bulsara J, Patel P, Soni A, Acharya S. A review: Brief insight into polycystic ovarian syndrome. Endocrine Metabol Sci 2021; 3: 100085.
[22]
Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab 2018; 29(12): 841-52.
[http://dx.doi.org/10.1016/j.tem.2018.08.005] [PMID: 30195991]
[23]
Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc 2019; 3(8): 1545-73.
[http://dx.doi.org/10.1210/js.2019-00078] [PMID: 31384717]
[24]
De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24(5): 633-67.
[http://dx.doi.org/10.1210/er.2002-0015] [PMID: 14570747]
[25]
Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012; 97(1): 18-22.
[http://dx.doi.org/10.1016/j.fertnstert.2011.11.036] [PMID: 22192137]
[26]
Ding H, Zhang J, Zhang F, et al. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. Front Endocrinol (Lausanne) 2021; 12: 741764.
[http://dx.doi.org/10.3389/fendo.2021.741764] [PMID: 34745009]
[27]
Yurtdaş G, Akdevelioğlu Y. A new approach to polycystic ovary syndrome: the gut microbiota. J Am Coll Nutr 2020; 39(4): 371-82.
[http://dx.doi.org/10.1080/07315724.2019.1657515] [PMID: 31513473]
[28]
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93(7): 2670-8.
[http://dx.doi.org/10.1210/jc.2008-0115] [PMID: 18460557]
[29]
Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study. Eur J Endocrinol 2018; 179(1): 1-11.
[http://dx.doi.org/10.1530/EJE-18-0175] [PMID: 29703793]
[30]
Papadakis GE, Dumont A, Bouligand J, et al. Non-classic cytochrome P450 oxidoreductase deficiency strongly linked with menstrual cycle disorders and female infertility as primary manifestations. Hum Reprod 2020; 35(4): 939-49.
[http://dx.doi.org/10.1093/humrep/deaa020] [PMID: 32242900]
[31]
Wawrzkiewicz-Jałowiecka A, Kowalczyk K, Trybek P, et al. In search of new therapeutics—molecular aspects of the PCOS pathophysiology: Genetics, hormones, metabolism and beyond. Int J Mol Sci 2020; 21(19): 7054.
[http://dx.doi.org/10.3390/ijms21197054] [PMID: 32992734]
[32]
Piri-Gharaghie T. Polycystic ovary syndrome and genetic factors influencing its development: A review article. Personalized Medicine Journal 2021; 6(23): 25-9.
[33]
Heidarzadehpilehrood R, Pirhoushiaran M, Abdollahzadeh R, et al. A review on CYP11A1, CYP17A1, and CYP19A1 polymorphism studies: Candidate susceptibility genes for polycystic ovary syndrome (PCOS) and infertility. Genes (Basel) 2022; 13(2): 302.
[http://dx.doi.org/10.3390/genes13020302] [PMID: 35205347]
[34]
Gorsic LK, Kosova G, Werstein B, et al. Pathogenic anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab 2017; 102(8): 2862-72.
[http://dx.doi.org/10.1210/jc.2017-00612] [PMID: 28505284]
[35]
Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-müllerian hormone in pathogenesis, diagnostic and treatment of PCOS. Int J Mol Sci 2021; 22(22): 12507.
[http://dx.doi.org/10.3390/ijms222212507] [PMID: 34830389]
[36]
Persani L, Rossetti R, Cacciatore C, Fabre S. Genetic defects of ovarian TGF-β-like factors and premature ovarian failure. J Endocrinol Invest 2011; 34(3): 244-51.
[http://dx.doi.org/10.1007/BF03347073] [PMID: 21297384]
[37]
Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 2021; 106(3): e1071-83.
[http://dx.doi.org/10.1210/clinem/dgaa839] [PMID: 33211867]
[38]
Girase T, Patil J, Tatiya A, Patil D, Patil M. Clomiphene citrate as nanomedicine assistance in ovulatory disorders and its hyphenated techniques. Materials Proceedings 2023; 14(1): 6.
[39]
Sadeghi HM, Adeli I, Calina D, et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci 2022; 23(2): 583.
[http://dx.doi.org/10.3390/ijms23020583] [PMID: 35054768]
[40]
Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod 2017; 32(8): 1631-8.
[http://dx.doi.org/10.1093/humrep/dex227] [PMID: 28854590]
[41]
Bansal S, Goyal M, Sharma C, Shekhar S. Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial. Int J Gynaecol Obstet 2021; 152(3): 345-50.
[http://dx.doi.org/10.1002/ijgo.13375] [PMID: 32920843]
[42]
Cunha A, Póvoa AM. Infertility management in women with polycystic ovary syndrome: a review. Porto Biomed J 2021; 6(1): e116.
[http://dx.doi.org/10.1097/j.pbj.0000000000000116] [PMID: 33532657]
[43]
Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand 2018; 97(10): 1162-7.
[http://dx.doi.org/10.1111/aogs.13395] [PMID: 29889977]
[44]
Wang L, Lv S, Li F, Bai E, Yang X. Letrozole versus clomiphene citrate and natural cycle: Endometrial receptivity during implantation window in women with polycystic ovary syndrome. Front Endocrinol (Lausanne) 2021; 11: 532692.
[http://dx.doi.org/10.3389/fendo.2020.532692] [PMID: 33537000]
[45]
Al-Fadhli R, Sylvestre C, Buckett W, Tan SL, Tulandi T. A randomized trial of superovulation with two different doses of letrozole. Fertil Steril 2006; 85(1): 161-4.
[http://dx.doi.org/10.1016/j.fertnstert.2005.07.1283] [PMID: 16412748]
[46]
Ahmed MSN, Kandil HO, Shaaban MM, Ramadan M. Combined chromium with letrozole versus letrozole only in induction of ovulation in patients with polycystic ovary syndrome: A Randomized controlled trial. Journal of Survey in Fisheries Sciences 2023; 10(3S): 3221-32.
[47]
Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001; 76(3): 517-24.
[http://dx.doi.org/10.1016/S0015-0282(01)01975-6] [PMID: 11532475]
[48]
Lapice E, Cocozza S, Riccardi G, Vaccaro O. Comment on: Zhang et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012;35:1388-1393. Diabetes Care 2013; 36(1): e18.
[http://dx.doi.org/10.2337/dc12-1993] [PMID: 23264301]
[49]
ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. J Endocrinol 2016; 229(1): 1-12.
[http://dx.doi.org/10.1530/JOE-15-0461] [PMID: 26769912]
[50]
Liu X, Zhang Y, Zheng S, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 2017; 87(6): 767-74.
[http://dx.doi.org/10.1111/cen.13454] [PMID: 28834553]
[51]
Stathatos N, Bourdeau I, Espinosa AV, et al. KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. J Clin Endocrinol Metab 2005; 90(9): 5432-40.
[http://dx.doi.org/10.1210/jc.2005-0963] [PMID: 15998767]
[52]
Wang X, Hao J, Zhang F, Li J, Kong H, Guo Y. Effects of female and male body mass indices on the treatment outcomes and neonatal birth weights associated with in vitro fertilization/intracytoplasmic sperm injection treatment in China. Fertil Steril 2016; 106(2): 460-6.
[http://dx.doi.org/10.1016/j.fertnstert.2016.04.021] [PMID: 27155105]
[53]
Sampeliling Y, Tahir AM, Hartono E, Kasim F. Clomiphene citrate and anastrozole: Effects on follicular diameter and endometrial thickness in polycystic ovary syndrome. Eur J Mol Clin Med 2020; 7(07): 2020.
[54]
Kader A, Thiyagarajan A, Mahfouz RZ, Sharma RK, Sabanegh E, Agarwal A. Sperm equilibration with a novel triple action cryoprotectant improves sperm kinetics compared to two combinations standard. Fertil Steril 2009; 92(3): S213.
[http://dx.doi.org/10.1016/j.fertnstert.2009.07.1493]
[55]
Ezcurra D, Rangnow J, Craig M, Schertz J. The Human Oocyte Preservation Experience (HOPE) a phase IV, prospective, multicenter, observational oocyte cryopreservation registry. Reprod Biol Endocrinol 2009; 7(1): 53.
[http://dx.doi.org/10.1186/1477-7827-7-53] [PMID: 19473532]
[56]
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (São Paulo) 2015; 70(11): 765-9.
[http://dx.doi.org/10.6061/clinics/2015(11)09] [PMID: 26602525]
[57]
Shi S, Hong T, Jiang F, Zhuang Y, Chen L, Huang X. Letrozole and human menopausal gonadotropin for ovulation induction in clomiphene resistance polycystic ovary syndrome patients. Medicine (Baltimore) 2020; 99(4): e18383.
[http://dx.doi.org/10.1097/MD.0000000000018383] [PMID: 31977842]
[58]
Ashry H, Aly T, Ragab AHMED. Comparison between letrozole with and without gonadotropins injection on pregnancy rates in infertile PCOS patients : A multicenter randomized observational trial. Evidence Based Women’s Health Journal 2022; 12(2): 157-65.
[http://dx.doi.org/10.21608/ebwhj.2021.113640.1164]
[59]
Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 2014; 16(2): 414.
[http://dx.doi.org/10.1007/s11906-013-0414-8] [PMID: 24407447]
[60]
Armanini D, Andrisani A, Bordin L, Sabbadin C. Spironolactone in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2016; 17(13): 1713-5.
[http://dx.doi.org/10.1080/14656566.2016.1215430] [PMID: 27450358]
[61]
Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 2013; 98(9): 3599-607.
[http://dx.doi.org/10.1210/jc.2013-1040] [PMID: 23846820]
[62]
Adeyanju OA, Falodun TO, Fabunmi OA, Olatunji LA, Soladoye AO. Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone. Chem Biol Interact 2019; 310: 108742.
[http://dx.doi.org/10.1016/j.cbi.2019.108742] [PMID: 31295448]
[63]
Olaniyi KS, Oniyide AA, Adeyanju OA, Ojulari LS, Omoaghe AO, Olaiya OE. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. Toxicol Appl Pharmacol 2021; 411: 115381.
[http://dx.doi.org/10.1016/j.taap.2020.115381] [PMID: 33359182]
[64]
Areloegbe SE, Peter MU, Oyeleke MB, Olaniyi KS. Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. BMC Endocr Disord 2022; 22(1): 224.
[http://dx.doi.org/10.1186/s12902-022-01143-y] [PMID: 36071485]
[65]
Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004; 89(6): 2756-62.
[http://dx.doi.org/10.1210/jc.2003-031780] [PMID: 15181054]
[66]
Esfandyari S, Chugh RM, Park H, Hobeika E, Ulin M, Al-Hendy A. Mesenchymal stem cells as a bio organ for treatment of female infertility. Cells 2020; 9(10): 2253.
[http://dx.doi.org/10.3390/cells9102253] [PMID: 33050021]
[67]
Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017; 6(12): 2173-85.
[http://dx.doi.org/10.1002/sctm.17-0129] [PMID: 29076267]
[68]
Saeed Y, Liu X. Mesenchymal stem cells to treat female infertility; future perspective and challenges: A review. Int J Reprod Biomed (Yazd) 2022; 20(9): 709-22.
[http://dx.doi.org/10.18502/ijrm.v20i9.12061] [PMID: 36340664]
[69]
Prayitno GD, Lestari K, Sartika CR, et al. Potential of Mesenchymal Stem Cells and Their Secretomes in Decreasing Inflammation Markers in Polycystic Ovary Syndrome Treatment: A Systematic Review. Medicines (Basel) 2022; 10(1): 3.
[http://dx.doi.org/10.3390/medicines10010003] [PMID: 36662487]
[70]
Natadisastra M, Kurniawan RH, Malik DM. Pentoxifylline as a therapy for thin endometrial lining in infertility. Indonesian Soc Obstetrician Gynecol 2015; 3(3): 3.
[71]
Vitale SG, Palumbo M, Rapisarda AMC, et al. Use of pentoxifylline during ovarian stimulation to improve oocyte and embryo quality: A retrospective study. J Gynecol Obstet Hum Reprod 2022; 51(6): 102398.
[http://dx.doi.org/10.1016/j.jogoh.2022.102398] [PMID: 35508290]
[72]
Rezvanfar MA, Saadat S, Shojaei Saadi HA, et al. Cellular and molecular mechanisms of pentoxifylline’s beneficial effects in experimental polycystic ovary. Theriogenology 2015; 83(6): 968-77.
[http://dx.doi.org/10.1016/j.theriogenology.2014.11.034] [PMID: 25557188]
[73]
Guarano A, Capozzi A, Cristodoro M, Di Simone N, Lello S. Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth? Nutrients 2023; 15(14): 3209.
[http://dx.doi.org/10.3390/nu15143209] [PMID: 37513627]
[74]
Zhao JF, Li BX, Zhang Q. Vitamin D improves levels of hormonal, oxidative stress and inflammatory parameters in polycystic ovary syndrome: a meta-analysis study. Ann Palliat Med 2021; 10(1): 169-83.
[http://dx.doi.org/10.21037/apm-20-2201] [PMID: 33545754]
[75]
Wang L, Lv S, Li F, et al. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China. Front Endocrinol (Lausanne) 2020; 11: 171.
[http://dx.doi.org/10.3389/fendo.2020.00171] [PMID: 32296394]
[76]
Roque M, Tostes ACI, Valle M, Sampaio M, Geber S. Letrozole versus clomiphene citrate in polycystic ovary syndrome: Systematic review and meta-analysis. Gynecol Endocrinol 2015; 31(12): 917-21.
[http://dx.doi.org/10.3109/09513590.2015.1096337] [PMID: 26479460]
[77]
Pritts EA. Letrozole for ovulation induction and controlled ovarian hyperstimulation. Curr Opin Obstet Gynecol 2010; 22(4): 289-94.
[http://dx.doi.org/10.1097/GCO.0b013e32833beebf] [PMID: 20592587]
[78]
Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2022; 9(9): CD010287.
[PMID: 36165742]
[79]
Rakic D, Jakovljevic V, Jovic N, et al. The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives. Biomedicines 2023; 11(4): 998.
[http://dx.doi.org/10.3390/biomedicines11040998] [PMID: 37189616]
[80]
Sinha B, Ghosal S. A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne) 2022; 13: 830401.
[http://dx.doi.org/10.3389/fendo.2022.830401] [PMID: 35265039]
[81]
Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2021; 106(10): 3019-33.
[http://dx.doi.org/10.1210/clinem/dgab408] [PMID: 34097062]
[82]
Guan Y, Wang D, Bu H, Zhao T, Wang H. The Effect of Metformin on Polycystic Ovary Syndrome in Overweight Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol 2020; 2020: 1-12.
[http://dx.doi.org/10.1155/2020/5150684] [PMID: 33014044]
[83]
Abbara A, Dhillo WS. Targeting Elevated GnRH Pulsatility to Treat Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2021; 106(10): e4275-7.
[http://dx.doi.org/10.1210/clinem/dgab422] [PMID: 34117885]
[84]
Abbara A, Phylactou M, Eng PC, et al. Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrhea. J Clin Endocrinol Metab 2023; 108(7): 1666-75.
[http://dx.doi.org/10.1210/clinem/dgad026] [PMID: 36653328]
[85]
Van Poppel H, Klotz L. Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists. Int J Urol 2012; 19(7): 594-601.
[http://dx.doi.org/10.1111/j.1442-2042.2012.02997.x] [PMID: 22416801]
[86]
Zhai XH, Zhang P, Wu FX, Wang AC, Liu PS. GnRH antagonist for patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer in fresh cycles. Exp Ther Med 2017; 13(6): 3097-102.
[http://dx.doi.org/10.3892/etm.2017.4309] [PMID: 28587385]
[87]
Collée J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol 2021; 37(10): 869-74.
[http://dx.doi.org/10.1080/09513590.2021.1958310] [PMID: 34338572]
[88]
Panda SR, Sharmila V, Kalidoss VK, Hota S. A triple-blind, randomized controlled trial, comparing combined letrozole and clomiphene versus only letrozole for ovulation induction in women with polycystic ovarian syndrome. Int J Gynaecol Obstet 2023; 161(1): 63-70.
[http://dx.doi.org/10.1002/ijgo.14476] [PMID: 36149885]
[89]
Tsiami AP, Goulis DG, Sotiriadis AI, Kolibianakis EM. Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. Hormones (Athens) 2021; 20(3): 449-61.
[http://dx.doi.org/10.1007/s42000-021-00289-z] [PMID: 34033068]
[90]
Merviel P, James P, Bouée S, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health 2021; 18(1): 13.
[http://dx.doi.org/10.1186/s12978-021-01073-3] [PMID: 33468143]
[91]
Shivani D, Sravanthi P, G NJ. Comparative study on efficacy of myo inositol over metformin in Polycystic ovary syndrome patients. Int J Reprod Contracept Obstet Gynecol 2021; 10(5): 1899-906.
[http://dx.doi.org/10.18203/2320-1770.ijrcog20211508]

Rights & Permissions Print Cite
Article Metrics
21
1
Wayfinder Image
TIMBC 2026
© 2025 Bentham Science Publishers | Privacy Policy